Malaysian Consensus Statement for the Diagnosis and Management of Acromegaly

Hussein, Zanariah; Bidin, Mohamed Long; Alias, Azmi; Thiagarajan, Muthukkumaran; Latif, Kartikasalwah Abdul; Ratnasingam, Jeyakantha; Seman, Wan Juani Wan; Nasruddin, Azraai

doi:10.15605/jafes.034.01.03

Cited by 4 publications

(14 citation statements)

References 64 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Magnetic resonance imaging of the pituitary is also requested. 17 Main treatment goals include tumour removal and normalisation of GH and IGF-1 levels, accompanied by the resolution of clinical symptoms and eventually, a reduction in long-term mortality. 17 The main therapeutic options for acromegaly include surgical resection of adenomas, medical treatment with dopamine agonists and somatostatin analogues, and radiotherapy.…”

Section: Resultsmentioning

confidence: 99%

“…17 Main treatment goals include tumour removal and normalisation of GH and IGF-1 levels, accompanied by the resolution of clinical symptoms and eventually, a reduction in long-term mortality. 17 The main therapeutic options for acromegaly include surgical resection of adenomas, medical treatment with dopamine agonists and somatostatin analogues, and radiotherapy. 8,11,17 Transsphenoidal surgery is often considered the first-line treatment for most patients, with medical therapy being reserved as second-line treatment for patients who refuse surgery to control hormone production and tumour growth.…”

Section: Resultsmentioning

confidence: 99%

“…17 The main therapeutic options for acromegaly include surgical resection of adenomas, medical treatment with dopamine agonists and somatostatin analogues, and radiotherapy. 8,11,17 Transsphenoidal surgery is often considered the first-line treatment for most patients, with medical therapy being reserved as second-line treatment for patients who refuse surgery to control hormone production and tumour growth. 8,[17][18][19] Patient presentation, demographics and treatment modalities vary greatly amongst countries and regions.…”

Section: Resultsmentioning

confidence: 99%

“…8,11,17 Transsphenoidal surgery is often considered the first-line treatment for most patients, with medical therapy being reserved as second-line treatment for patients who refuse surgery to control hormone production and tumour growth. 8,[17][18][19] Patient presentation, demographics and treatment modalities vary greatly amongst countries and regions. There was no prior data on acromegaly in Malaysia, hence, the Malaysian Endocrine and Metabolic Society (MEMS) established the acromegaly disease registry in 2013.…”

Section: Resultsmentioning

confidence: 99%

“…Regardless of adenoma size, majority of patients received monotherapy with most patients undergoing surgery alone In terms of medical treatment, guidelines recommend the use of somatostatin analogues first and consider dopamine agonists in milder cases. [17][18][19] However, dopamine agonists are given more often used than somatostatin analogues in practice due to its ease of administration, wide accessibility and affordability. In Malaysia, the use of somatostatin analogues is restricted and tightly regulated.…”

Section: Table 1 Patient Baseline Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly: Real-World Evidence from the Malaysian Acromegaly Registry

Bidin

Khan²,

Tan

et al. 2023

JAFES

View full text Add to dashboard Cite

Objective. This study aims to report the demographic features of patients with acromegaly, the disease burden, and the corresponding treatment patterns and outcomes in Malaysia.Methodology. This is a retrospective study that included patients from the Malaysian Acromegaly registry who were diagnosed with acromegaly from 1970 onwards. Data collected included patient demographics, clinical manifestations of acromegaly, biochemical results and imaging findings. Information regarding treatment modalities and their outcomes was also obtained.Results. Registry data was collected from 2013 to 2016 and included 140 patients with acromegaly from 12 participating hospitals. Median disease duration was 5.5 years (range 1.0 -41.0 years). Most patients had macroadenoma (67%), while 15% were diagnosed with microadenoma. Hypertension (49.3%), diabetes (37.1%) and hypopituitarism (27.9%) were the most common co-morbidities for patients with acromegaly. Majority of patients had surgical intervention as primary treatment (65.9%) while 20.7% were treated medically, mainly with dopamine agonists (18.5%). Most patients had inadequate disease control after first-line treatment regardless of treatment modality (79.4%). Conclusion.This registry study provides epidemiological data on patients with acromegaly in Malaysia and serves as an initial step for further population-based studies.

show abstract

Section: Resultsmentioning

confidence: 99%